Improving Health Equity Through Standardization and Selective Expansion of Genetic Testing in Transthyretin Amyloidosis
Authors:
Open Access
- 22 November 2024
- journal article
- editorial
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (23) , e036995
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Hereditary Transthyretin Amyloidosis in Patients Referred to a Genetic Testing ProgramJournal of the American Heart Association, 2024
- Efficacy and Safety of Acoramidis in Transthyretin Amyloid CardiomyopathyNew England Journal of Medicine, 2024
- Eplontersen for Hereditary Transthyretin Amyloidosis With PolyneuropathyJAMA, 2023
- 2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac AmyloidosisJACC, 2023
- Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trialAmyloid, 2022
- Transthyretin V142I Genetic Variant and Cardiac Remodeling, Injury, and Heart Failure Risk in Black AdultsJACC: Heart Failure, 2022
- Presence of the V122I Variant of Hereditary Transthyretin-Mediated Amyloidosis Among Self-Reported White Individuals in a Sponsored Genetic Testing ProgramCirculation: Genomic and Precision Medicine, 2021
- Screening for ATTR amyloidosis in the clinic: overlapping disorders, misdiagnosis, and multiorgan awarenessHeart Failure Reviews, 2021
- Tafamidis Treatment for Patients with Transthyretin Amyloid CardiomyopathyNew England Journal of Medicine, 2018
- Afro-Caribbean Heart Failure in the United KingdomCirculation: Heart Failure, 2016